MX393700B - Agente para prevenir o tratar la ataxia espinocerebelosa. - Google Patents

Agente para prevenir o tratar la ataxia espinocerebelosa.

Info

Publication number
MX393700B
MX393700B MX2019014302A MX2019014302A MX393700B MX 393700 B MX393700 B MX 393700B MX 2019014302 A MX2019014302 A MX 2019014302A MX 2019014302 A MX2019014302 A MX 2019014302A MX 393700 B MX393700 B MX 393700B
Authority
MX
Mexico
Prior art keywords
prevent
ataxia
agent
spinocerebelloal
treating
Prior art date
Application number
MX2019014302A
Other languages
English (en)
Other versions
MX2019014302A (es
Inventor
Hiroshi Kobayashi
Tomohiro Okuda
Yoshihiko Matsumoto
Original Assignee
Fujifilm Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Toyama Chemical Co Ltd filed Critical Fujifilm Toyama Chemical Co Ltd
Publication of MX2019014302A publication Critical patent/MX2019014302A/es
Publication of MX393700B publication Critical patent/MX393700B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se dirige al problema de proporcionar un agente terapéutico o profiláctico superior para la ataxia espinocerebelosa. El 1-(3-(2-(1-benzotiofen-5-il)etoxi)propil)azetidin-3-ol o una sal del mismo tiene un efecto de supresión de la atrofia cerebral, en particular, la atrofia cerebelosa, y por consiguiente es útil como un agente terapéutico o profiláctico para la ataxia espinocerebelosa. Por lo tanto, es posible prevenir o tratar la atrofia cerebelosa observada en la ataxia espinocerebelosa por medio de la administración del 1-(3-(2-(1-benzotiofen-5-il)etoxi)propil)azetidin-3-ol o una sal del mismo.
MX2019014302A 2017-06-02 2018-06-01 Agente para prevenir o tratar la ataxia espinocerebelosa. MX393700B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2017109885 2017-06-02
JP2017128472 2017-06-30
JP2017145101 2017-07-27
PCT/JP2018/021224 WO2018221730A1 (ja) 2017-06-02 2018-06-01 脊髄小脳変性症予防または治療剤

Publications (2)

Publication Number Publication Date
MX2019014302A MX2019014302A (es) 2022-07-05
MX393700B true MX393700B (es) 2025-03-24

Family

ID=64454849

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014302A MX393700B (es) 2017-06-02 2018-06-01 Agente para prevenir o tratar la ataxia espinocerebelosa.

Country Status (15)

Country Link
US (1) US11660287B2 (es)
EP (1) EP3632430A4 (es)
JP (1) JP7133547B2 (es)
KR (1) KR20190138696A (es)
CN (1) CN110691593B (es)
AU (1) AU2018277981B2 (es)
BR (1) BR112019024881A2 (es)
CA (1) CA3067455C (es)
IL (1) IL270910B2 (es)
MX (1) MX393700B (es)
NZ (1) NZ759647A (es)
RU (1) RU2728717C1 (es)
SG (1) SG11201911515QA (es)
WO (1) WO2018221730A1 (es)
ZA (1) ZA201907974B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX393052B (es) 2017-06-02 2025-03-24 Fujifilm Toyama Chemical Co Ltd Agente para prevenir o tratar atrofia cerebral.
US11666551B2 (en) 2017-06-02 2023-06-06 Fujifilm Toyama Chemical Co., Ltd. Agent for reducing amount of amyloid β protein
WO2018221728A1 (ja) 2017-06-02 2018-12-06 富山化学工業株式会社 アルツハイマー型認知症予防または治療剤
EP3705121B1 (en) 2017-10-30 2023-08-30 FUJIFILM Toyama Chemical Co., Ltd. Emopamil binding protein binding agent and use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69526918T2 (de) * 1994-08-05 2002-12-19 Suntory Ltd., Osaka Arzneimittel gegen spinocerebellare degeneration
CA2302808C (en) 1997-09-05 2010-05-18 Human Genome Sciences, Inc. 50 human secreted proteins
GB9824207D0 (en) 1998-11-04 1998-12-30 Zeneca Ltd Neurological disorders
JP4398247B2 (ja) 2001-10-19 2010-01-13 富山化学工業株式会社 アルキルエーテル誘導体またはその塩
USRE42327E1 (en) 2002-06-14 2011-05-03 Toyama Chemical Co., Ltd. Medicinal compositions improving brain function and method for improving brain function
PL1614419T3 (pl) 2003-04-17 2013-01-31 Toyama Chemical Co Ltd Środek zapobiegawczy/lek przeciwko chorobom nerwu wzrokowego zawierający pochodne eteru alkilowego lub ich sole
TWI350754B (en) * 2004-09-09 2011-10-21 Shionogi & Co A pharmaceutical composition for treating spinocerebellar ataxia
JP5196641B2 (ja) * 2004-09-09 2013-05-15 塩野義製薬株式会社 脊髄小脳変性症治療剤
US20090093453A1 (en) 2006-04-26 2009-04-09 Toyama Chemical Co., Ltd Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
US8119625B2 (en) 2006-04-26 2012-02-21 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
BRPI0909782B8 (pt) 2008-03-04 2021-05-25 Vernalis R&D Ltd composto derivado de azetidina e composição farmacêutica compreendendo dito composto
FR2934596B1 (fr) 2008-07-30 2015-04-10 Trophos Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation
US20110262442A1 (en) * 2009-11-06 2011-10-27 Adenios, Inc. Compositions for treating cns disorders
RU2625767C2 (ru) 2012-02-22 2017-07-18 Тояма Кемикал Ко., Лтд. Твердая фармацевтическая композиция, содержащая 1-(3-(2-(1-бензотиофен-5-ил)этокси)пропил)азетидин-3-ол или его соль
JP6397407B2 (ja) 2012-07-19 2018-09-26 ドレクセル ユニバーシティ 細胞タンパク質ホメオスタシスを調節するためのシグマ受容体リガンド
RU2647585C2 (ru) * 2012-10-01 2018-03-16 Ф. Хоффманн-Ля Рош Аг Бензимидазолы в качестве активных агентов для центральной нервной системы
JP5837726B1 (ja) 2014-01-31 2015-12-24 富山化学工業株式会社 アルキルエーテル誘導体またはその塩を含有する神経損傷後のリハビリテーション効果促進剤
WO2015163318A1 (ja) 2014-04-25 2015-10-29 レジリオ株式会社 アルツハイマー病の治療剤を含む、神経細胞の軸索の機能不全が関与する疾患の治療剤
WO2015188368A1 (en) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles
WO2016051799A1 (ja) 2014-10-01 2016-04-07 学校法人同志社 ２－アミノヒドロキノン誘導体及びタウ凝集阻害剤
WO2016124508A1 (en) 2015-02-02 2016-08-11 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives
US20160324851A1 (en) 2015-05-07 2016-11-10 Axovant Sciences, Ltd. Methods of treating a neurodegenerative disease
US10238632B2 (en) 2015-06-11 2019-03-26 Fujifilm Toyama Chemical Co., Ltd. Sigma receptor-binding agent
WO2017111005A1 (ja) * 2015-12-25 2017-06-29 富山化学工業株式会社 １－（３－（２－（１－ベンゾチオフェン－５－イル）エトキシ）プロピル）アゼチジン－３－オールまたはその塩を含む錠剤
US11666551B2 (en) 2017-06-02 2023-06-06 Fujifilm Toyama Chemical Co., Ltd. Agent for reducing amount of amyloid β protein
KR20220101001A (ko) 2017-06-02 2022-07-18 후지필름 도야마 케미컬 가부시키가이샤 타우병증 예방 또는 치료제
MX393052B (es) 2017-06-02 2025-03-24 Fujifilm Toyama Chemical Co Ltd Agente para prevenir o tratar atrofia cerebral.
WO2018221728A1 (ja) 2017-06-02 2018-12-06 富山化学工業株式会社 アルツハイマー型認知症予防または治療剤
EP3705121B1 (en) 2017-10-30 2023-08-30 FUJIFILM Toyama Chemical Co., Ltd. Emopamil binding protein binding agent and use thereof

Also Published As

Publication number Publication date
SG11201911515QA (en) 2020-01-30
BR112019024881A2 (pt) 2020-06-16
EP3632430A1 (en) 2020-04-08
US11660287B2 (en) 2023-05-30
US20200085787A1 (en) 2020-03-19
EP3632430A4 (en) 2020-06-10
AU2018277981A1 (en) 2019-12-19
IL270910B1 (en) 2023-11-01
CN110691593B (zh) 2023-05-02
ZA201907974B (en) 2022-03-30
NZ759647A (en) 2022-02-25
JPWO2018221730A1 (ja) 2020-04-09
JP7133547B2 (ja) 2022-09-08
IL270910A (en) 2020-01-30
RU2728717C1 (ru) 2020-07-30
KR20190138696A (ko) 2019-12-13
MX2019014302A (es) 2022-07-05
CA3067455A1 (en) 2018-12-06
IL270910B2 (en) 2024-03-01
WO2018221730A1 (ja) 2018-12-06
CA3067455C (en) 2021-11-23
CN110691593A (zh) 2020-01-14
AU2018277981B2 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
EA201500953A1 (ru) 3-ацетиламино-1-(фенилгетероариламинокарбонил или фенилгетероарилкарбониламино)бензольные производные для лечения гиперпролиферативных нарушений
EA201892505A1 (ru) Амидозамещенные производные пиридинилтриазола и их применение
MX2018000412A (es) Moduladores de diaciglicerol aciltransferasa 2 (dgat2).
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
ECSP13013035A (es) Combinaciones de compuestos activos que comprenden un derivado de (tio)carboxamida y un compuesto fungicida
TN2019000136A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
EA201170349A1 (ru) Модуляторы mif
MX393700B (es) Agente para prevenir o tratar la ataxia espinocerebelosa.
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
MX2019014041A (es) Inhibidores pirazolicos de magl.
MX2017012545A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
EA201990044A1 (ru) Гетероциклические соединения в качестве антибактериальных средств
MX393052B (es) Agente para prevenir o tratar atrofia cerebral.
MX2020006191A (es) Bacteriocinas terapeuticas.
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
JOP20210158A1 (ar) مُعَدِّلات التعبير الجيني عن hsd17b13
CL2016002497A1 (es) “compuestos derivados de heterociclos condensados sustituidos, moduladores de gpr119; composición farmacéutica que los comprende; útiles en el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados”. pct
NI202000085A (es) Moduladores de la expresión de apol1
AR077372A1 (es) Composiciones y metodos para tratar infecciones oftalmicas oticas o nasales
MX394436B (es) Agente para prevenir o tratar la tauopatia.
NZ764310A (en) Antibacterial compounds
MX2017012535A (es) Compuestos hetorociclicos novedosos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
EA201791322A1 (ru) Комбинации активных соединений, которые содержат (тио)карбоксамидное производное и фунгицидное(ые) соединение(я)